The Koch Institute for Integrative Cancer Research at MIT

Mosaic of colored tiles and images of research and people

Celebrating 50 years of collaboration, innovation, and curiosity in cancer research at MIT

Our Research Areas

From fundamental discoveries to engineering advances, we strategically pursue five areas of research that, across tumor types, are critical for rapid progress toward defeating cancer.


Clinical progress for hitchhiking cancer vaccine

MIT News

Elicio Therapeutics saw promising results in clinical trials for its therapeutic cancer vaccine based on technology developed in the Irvine Lab and funded in part by the Bridge Project. Once in the bloodstream, the vaccine hitches a ride on the protein albumin to the lymph nodes, where large populations of immune cells can be taught to attack cancer cells. Phase 1 data showed that the vaccine, which targeted two variations of the cancer gene KRAS, provoked strong antitumor immune responses in pancreatic cancer patients. Elicio is currently testing a vaccine that targets seven KRAS mutants, and plans to address other KRAS-driven cancers, such as colorectal and non-small cell lung cancers.

At the Koch Institute for Integrative Cancer Research, scientists and engineers work together to solve some of the most difficult problems in cancer. We ask big questions in strategic areas, where the answers have big impacts on how we understand and treat cancer.